Taken together, these data support the hypothesis that nuclear PTTG1 can promote tumor progression, driving MMP-2 levels, and indicates that the subcellular localization of this securin represents a specific feature of seminoma among TGCTs, suggesting its possible use as a prognostic factor in clinical practice. This evidence concerns the gene PTTG1 and neoplasm.